|
|
Article: New study for ddC. (dideoxycytidine)
- Article from:
- FDA Consumer
- Article date:
- September 1, 1990
CopyrightCOPYRIGHT 1990 U.S. Government Printing Office. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
New Study for ddC
A new study to test the safety of the experimental anti-AIDS drug ddC (dideoxycytidine) has been sanctioned by FDA.
This protocol allows access to ddC for patients with AIDS or advanced ARC who can tolerate neither zidovudine (commonly called AZT), the standard treatment, nor dideoxyinosine (ddI), an experimental anti-viral drug currently available to certain patients through clinical testing and expanded access protocols. In addition, patients who have had progression of disease while on AZT and who were also ddI intolerant will be given ddC.
AZT can cause severe anemia and low white blood cell counts, while ddI may cause ...